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Survivin is an essential mitotic protein 
that is over expressed in many cancers 
and its presence is correlated with 
increased resistance to radiation and 
chemotherapy.  Here we demonstrate 
that sending survivin into the nucleus 
accelerates its degradation in a cdh1 
dependent manner, abolishes the 
radio resistance normally conferred to 
cells by its over expression, and 
prevents survivin from inhibiting 
apoptosis without affecting its mitotic 
localisation.  Our data suggest that 
targeting survivin to the nucleus 
provides an efficient means of 
eliminating it from the cell and may 
prove a novel strategy in cancer 
treatment, particularly in 
combination with radiotherapy. 
 
Introduction. 
Survivin is an essential mitotic 
protein that can also inhibit apoptosis. It 
is up regulated in the vast majority of 
human cancers and, unlike in normal 
proliferating cells, in cancer cells it can 
be present throughout interphase, 
indicating a loss of cell-cycle regulation. 
Deregulated survivin expression has 
been reported at both mRNA and protein 
levels and correlates with increased 
resistance to radio- and chemotherapies.  
In tumour biopsies, survivin has been 
localised to the nucleus and cytoplasm 
or both, and a number of studies have 
implied that differences in patient 
prognosis correlate with differences in 
nuclear or cytoplasmic 
compartmentalisation. However, there is 
no clear consensus from these studies 
(1).  
We, and others, have recently 
shown that survivin is a nuclear-
cytoplasmic shuttling protein, which is 
predominantly cytoplasmic due, in part, 
to an active nuclear exportation signal 
(NES) in its linker region (2-8). 
Importantly, unlike wild type survivin, 
NES mutants are unable to protect cells 
against X-irradiation or TRAIL induced 
apoptosis (4), suggesting that relocating 
survivin to the nucleus during interphase 
may be key to inhibiting its 
cytoprotective activity. These data 
highlight the importance of regulating, 
not only the level, but also the 
localisation of survivin in cancer cells. 
To date, any link between sub 
cellular compartmentalisation and 
survivin stability has not been 
addressed; such regulation would have 
implications in terms of the protein’s 
behaviour, both in the etiology of 
tumourigenesis and in the design of 
chemotherapeutic targeting of the 
protein. To examine the consequences of 
expressing survivin in the nucleus rather 
than the cytoplasm, we have fused wild 
type survivin-GFP to nuclear 
localisation signals (NLS). We herein 
report that nuclear survivin is subject to 
accelerated proteosomal degradation and 
an abrogation of the cytoprotection 
otherwise afforded by its 
overexpression.  Together our results 
suggest a possible mechanism for 
eliminating survivin from interphase 
cells with a concomitant sensitisation to 
apoptotic stimuli.  
 
Experimental Procedures. 
Unless otherwise stated tissue 
culture reagents were from Invitrogen, 
and all other chemicals from Sigma. 
 
Cell culture and generation of stable 
lines. 
HeLa cells were maintained at 37ºC with 
5% CO2 in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 
10% foetal calf serum, 
penicillin/streptomycin, 500 μg/ml G418 
and fungizome. Lines made specifically 
for the study were survivinNLS(LANA)-
GFP, survivinNLS(SV40)-GFP and GFPNLS-
GFP.  All other lines have been 
described previously (4,9). Proteins of 
interest were expressed by FuGene-6 
(Roche) mediated transfection of 
pcDNA3.1 constructs and selected with 
G418 (500 μg/ml). Cells stably 
expressing proteins of interest were 
maintained similarly but were grown in 
the presence of G418.  Prior to 
experimentation, lines were sorted using 
an LSRII fluorescence activated cell 
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sorter (BD Biosciences) to ensure 
homogeneous populations, and used 
within five passages of sorting. 
 
Nuclear-cytoplasmic fractionation. 
Cells were harvested, washed in PBS 
then resuspended in ice-cold hypotonic 
buffer (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 1 mM DTT, plus 
protease inhibitors). Cells were sheared 
by passage through a 25 gauge needle 15 
times. The lysates were centrifuged at 
11,000g for 20 minutes at 4ºC and the 
supernatant was collected. The pellet 
was resuspended in 20 mM HEPES (pH 
7.9), 1.5 mM MgCl2, 0.42 M NaCl, 0.2 
mM EDTA, 25% (v/v) glycerol, 1 mM 
DTT, plus protease inhibitors. Lysates 
were centrifuged at 21,000g for 5 
minutes to obtain nuclear fractions. 
Protein concentration was determined 
using a Bradford Reagent protein assay 
(BioRad) and equal concentration of 
cytoplasmic and nuclear extracts were 
used for immunoblotting analyses. 
 
Immunoblotting. 
Standard procedures were followed for 
SDS-PAGE, immunoblotting and 
enhanced chemiluminesent detection 
(GE Healthcare).  Antibodies used were 
goat anti-survivin (1/500; R and D 
Systems), anti-myc (9E10, 1/500), anti-
tubulin (1/2000; B512), anti-GFP 
(1/500; 3E1; CR-UK), anti-XRCC1 (a 
gift from K.Caldecott), anti-aurora-B 
kinase (anti-AIM1, 1/250, Transduction 
Labs), and anti-cdh1 (AbCam). Horse-
radish peroxidase conjugated secondary 
antibodies were from Dako Cytometrics 
and were used at dilutions of 1/1000-
1/5000. 
 
Radiolabelling and 
Immunoprecipitation. 
 In vivo labelling was carried 
out by incubating 106 cells with 50 
mCi/ml 35S-methionine. To 
determine the rate of protein 
turnover, cells were pulsed as above 
and chased for up to 16 h in the 
presence of an excess of unlabeled 
amino acids. After radiolabelling 
cells were lysed for 30 minutes on 
ice in 500 μl RIPA buffer (20 mM 
Tris (pH 8), 137 mM NaCl, 0.5 mM 
EDTA, 10% glycerol, 1% Nonidet P-
40, 0.1% SDS, 1% deoxycholate with 
1 mM -glycerophosphate, and 1 
µg/ml each of the protease inhibitors 
AEBSF, chymostatin, leupeptin, 
antipain, pepstatin A), containing 
2mM MgCl2 and 25U/ml benzonase 
(VWR). Lysates were then cleared 
and supernatants incubated for 1.5 h 
at 4°C with 2 µg of a polyclonal anti-
survivin (Novus) antibody. Protein G 
Sepharose beads were then added (40 
µl of a 50% slurry in lysis buffer), 
and samples incubated for a further 2 
h at 4°C. Samples were then washed, 
separated by SDS-PAGE, and band 
intensities quantified from the dried 
gel using a Storm 860 
PhosphorImager (GE Healthcare).  
Cold immunoprecipitations were 
performed similarly and analysed by 
immunoblotting.  
  
Fluorescence microscopy. 
Cells were grown on poly-l-lysine 
coated coverslips then fixed with 4% 
formaldehyde (Science Services), and 
permeabilised with 0.15% triton, both in 
PBS for 5 and 2 minutes respectively 
(37ºC). Interphase cells were probed 
with anti-lamin B antibodies (C20: 
1/500, Santa Cruz), and mitotic cells 
were probed with anti-tubulin antibodies 
(1/2000; B512), followed by anti-goat or 
anti-mouse Texas red secondary 
antibodies (1/200; Vector Labs).  Cells 
were mounted in Vectashield with DAPI 
and viewed using an inverted Olympus 
microscope fitted with an x 63 oil 
immersion lens, (NA 1.35). Images were 
captured using a Hammamatsu CCD 
camera and Delta Vision Spectris 
software (Applied Precision). JPEG snap 
shots were prepared as 3D projections of 
deconvolved z-stacks. Fields of cells 
were photographed using a Zeiss 
Axioplan microscope, fitted with an x 40 
objective and operated using Simple PCI 
software.  
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RT-PCR. 
RNA was extracted from 107 
asynchronously growing Hela cells 
using the RNAqueous kit (Ambion). 
RNA samples were incubated for 1 h at 
37°C with RNAase free DNAase 
(Promega) to eliminate any 
contaminating DNA. After inactivation 
of the DNAase (70°C for 10 minutes), 
RNA was precipitated with 1 volume of 
isopropanol, and then resuspended in 
RNAse free water. 4 μg of each sample 
was used for cDNA synthesis using 
First-Strand cDNA synthesis kit (GE 
Healthcare). cDNA for exogenous 
survivin-GFP (and variants) was 
amplified using a forward primer, which 
annealed to the 5’ end of  survivin open 
reading frame and a reverse primer, 
which annealed to the 5’-end of GFP 
open reading frame.  
 
Drug Treatments, Cell 
Synchronisation and FACS Analysis. 
To inhibit protein translation cells were 
treated with 50 μg/ml cycloheximide. To 
inhibit protein degradation mediated by 
the proteasome, cells were treated with 
50 μM MG132 for 6 h, or 20 μM 
MG132 for 16 h. When working with 
the NLS tagged versions of survivin 
MG132 treatment prior to 
cycloheximide treatment was necessary 
to enable detection of these proteins at 
the outset of the experiment. To inhibit 
CRM1 dependent nuclear export, cells 
were treated with 6-10 ng/ml leptomycin 
B (LMB; VWR) for 4 h, 6 h or 12 h as 
indicated. For G1 synchrony, cells were 
treated overnight with 400 μM 
mimosine. Cell cycle distribution was 
determined by measuring the DNA 
content using flow cytometry. Briefly, 
105 cells were harvested, washed and 
fixed with 70% ice cold ethanol.  Cells 
were then washed with PBS, and 
resuspended in 200 µl of propidium 
iodide solution containing 50 μg/ml PI 
and 100 μg/ml RNase A (MP 
Biomedicals, UK). Propidium iodide 
stained cells were analysed with a 
FACScan cytometer using CellQuest 
software (Becton Dickinson). 
 
Analysis of APC/C modulators. 
To over express cdc20 and cdh1, 
pcDNA-cdc20-myc and pcDNA-cdh1-
myc (gifts from Dr. Katya Ravid, 
University of Massachusetts, Boston, 
USA) were transiently transfected into 
HeLa cells using FuGene-6 (Roche) and 
expression assessed 24 h later by 
immunoblotting using anti-myc 
antibodies (9E10).  
 To deplete cdh1 predesigned 
cdh1 siRNA oligos (Ambion, ABI 
Biosystems), were transfected into HeLa 
cells using Hyperfect (Qiagen). 
Depletion was assessed by 
immunoblotting with anti-cdh1 
antibodies (AbCam), 24 h post-
transfection. 
 
X-irradiation and clonogenic survival. 
Cells were seeded at low density (500-
1000 cells per dish) in 9 cm2  petri dishes 
and allowed 2 h to attach, before 
exposure to X-irradiation using an Hs-
X-Ray System (A.G.O. Installations 
Ltd., Reading, UK). Seven days post-
irradiation, colonies were stained with 
methylene blue (1 h room temperature), 
dried, then rinsed with H2O and colonies 
of 50 cells or more were counted.  
 
Apoptosis Assays. 
To induce apoptosis by the extrinsic 
caspase-8/caspase-3 pathway, 
exponentially growing cells were treated 
with 250 μg/ml recombinant human 
TRAIL (Pepro Tech EC Ltd) for 60 or 
90 minutes.  Cells were lysed (45 
minutes, RT) in mammalian protein 
extraction buffer, MPER (Pierce), 
supplemented with 1 mM EDTA, 1 
μg/ml pepstatin A and 1 mM AEBSF, at 
a concentration of 106 cell equivalents 
per ml. Lysates were then cleared, snap 
frozen in liquid nitrogen and stored at –
80ºC. 
 To determine apoptotic activity, 
tetrapeptide cleavage assays were 
performed in a 96 well plate. Briefly, 5 
ng/ml of the caspase-3 specific 
tetrapeptide substrate (DEVD-AMC; 
Biomol) was incubated at 37ºC for 1 h 
with 20-50 μl of whole cell lysate 
prepared in MPER (Pierce), in 20 mM 
HEPES (pH 7.5) with 10% glycerol and 
1 mM DTT . Relative fluorescence 
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release was measured  using a 
Spectramax Gemini fluorimeter 
(Molecular Devices) with excitation set 
at 380 nm and emission at 440 nm.  
 
Cell Viability Assay. 
Cells were seeded at a density of 
104 per well, in a 24 well dish, then 
irradiated at the doses indicated.  Seven 
days later, cells were incubated with 
thiazolyl blue tetrazolium bromide 
(MTT) and cell viability assessed using 
a Spectramax Gemini fluorimeter 
(Molecular Devices).   
 
  
Results. 
Endogenous survivin is preferentially 
degraded in the nucleus. 
It has previously been shown that 
survivin is subject to proteasome-
mediated degradation, as levels of 
endogenous survivin increase after 
treatment with MG132 (17). This 
increase is not due to accelerated 
synthesis as immunoprecipitation of 
endogenous survivin pulse labelled with 
35S methionine for 2 h, actually showed 
decreased incorporation of 35S (thus 
decreased synthesis) in the presence of 
MG132 (data not shown).  To 
investigate any dependence of survivin 
stability on sub cellular 
compartmentalisation, we have 
fractionated asynchronous HeLa cells 
following MG132 treatment and 
analysed the level of endogenous 
survivin in nuclear and cytoplasmic 
fractions (Figure 1A). Using tubulin and 
XRCC1 as markers of cytoplasmic and 
nuclear fractions respectively, we 
observed a selective increase in nuclear 
levels of endogenous survivin following 
MG132 treatment. Consistent with this 
finding, when endogenous survivin was 
sequestered in the nucleus by treatment 
with the exportin inhibitor LMB, its 
expression was reduced (Figure 1B) by 
approximately 30%.  Together, these 
data suggest that nuclear survivin may 
be less stable than survivin localised to 
the cytoplasm. 
 
Generation of stable lines expressing 
survivinNLS-GFP.  
Survivin is a nuclear-cytoplasmic 
shuttling protein, which is primarily 
cytoplasmic when over expressed. To 
further investigate post-translational 
regulation of survivin levels we sought 
to send survivin to the nucleus. To this 
end we fused full length human survivin 
to two separate NLS sequences, the 
bipartite LANA sequence 
RRHERPTTRRIRHRKLRS (10), and 
the monopartite SV40 T-antigen NLS 
sequence PKKKRKV (11), hereinafter 
referred to as survivinNLS(LANA)-GFP and 
survivinNLS(SV40)-GFP respectively.  As 
these survivin constructs are expressed 
from the CMV promoter, they are not 
subject to transcriptional regulation, thus 
they enable us to investigate changes in 
protein level attributed solely to 
posttranslational regulation.  HeLa cell 
lines were generated that stably over 
expressed these versions of survivin and 
were FACS sorted to homogeneity prior 
to use.  As shown in Figure 2A survivin-
GFP was predominantly cytoplasmic 
while both survivinNLS(LANA)-GFP and 
survivinNLS(SV40)-GFP were retained in 
the nucleus (see Figures 2B and C). 
Lines were also generated that expressed 
GFP or GFPNLS-GFP, for use as controls 
(data not shown).  Importantly, the 
presence of an NLS on survivin did not 
hamper its localisation in mitosis, where 
both constructs were found at the same 
locations as survivin-GFP: the 
centromeres, midzone, and midbody, 
during prometaphase, anaphase and 
cytokinesis respectively, (Figures 2D-F). 
 
Survivin-NLS-GFP is degraded more 
rapidly than Survivin-GFP. 
From our low magnification 
fluorescence data in Figure 2 (right 
panels A-C), we noted that the level of 
expression of survivinNLS-GFP in both 
lines appeared lower than for the line 
expressing survivin-GFP. By RT-PCR, 
we confirmed that the transcripts to 
these forms were present (Figure 3A), 
and therefore mRNA was still being 
expressed.  We also ascertained that 
these forms did not have different rates 
of protein synthesis (see Figure 3G). 
Thus we reasoned that the differential 
expression was due to differences in the 
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rates of protein turnover.  To examine 
this we immunoblotted whole cell 
extracts from asynchronous populations 
of cells expressing survivin-GFP or 
survivinNLS-GFP.  Strikingly, while 
survivin-GFP was abundantly present in 
untreated asynchronous cells, 
survivinNLS(LANA)-GFP was barely 
detectable (Figure 3B).  Furthermore, 
while 6 h treatment with MG132 caused 
only a modest (1.08 fold) increase in 
survivin-GFP expression (Figure 3B and 
C), survivinNLS-GFP levels rose at steady 
rate to 3.9 fold (Figure 3B and C),  
demonstrating that the stability of 
survivinNLS-GFP is proteasome 
dependent, as is the case for the 
endogenous protein (Figure 1A).  
Similar results were obtained with 
survivinNLS(SV40)-GFP.  As a control we 
also compared GFP expression in cells 
expressing GFP and GFPNLS-GFP. No 
differences in GFP expression were 
observed in these lines, indicating that 
the increased rate of turnover was not an 
artefact of the tag (data not shown).   
To determine the relative 
stability of these versions of survivin, 
cells were treated with the translational 
inhibitor, cycloheximide (Figures 3D 
and E). Due to the rapid clearance of the 
nuclear forms of survivin, this 
experiment had to be carried out after 
pre-treatment with MG132 (see lanes 1 
and 2, Figure 3E).  Note, 16 h treatment 
with MG132 did not affect cell cycle 
stage as assessed by FACS analysis 
(data not shown).  Over a 16 h time 
course survivinNLS(LANA)-GFP was 
degraded  much more rapidly than 
survivin-GFP (Figure 3D and E ), as is 
evident by the quantitation in Figure 3F. 
We also noted that the addition of an 
NLS to GFP itself did not decrease the 
stability of GFP (data not shown). 
To exclude the possibility that 
the level of survivin expression was due 
to changes in the rate of protein 
synthesis, we next pulse labelled 
survivin-GFP and survivinNLS-GFP cells 
with 35S methionine.  First, cells were 
treated with MG132 for 4 h, then 
exposed to 35S methionine and incubated 
for a further 2 h (Figure 3G).  Lysates 
were then prepared from each 
population and survivin-GFP or 
survivinNLS-GFP immunoprecipitated 
from the extracts using anti-survivin 
antibodies. As shown in Figure 3G 
survivin-GFP and survivinNLS-GFP 
incorporated 35S-methionine to similar 
levels as quantified using a 
Phosphorimager (pixel intensities of 
bands 245246 and 246678 respectively).  
Next, we followed the pulse labelling 
with a cold chase after the removal of 
MG132 and addition of cycloheximide.  
In accordance with our immunblotting 
experiments in Figures 3D-F, the rate of 
survivinNLS-GFP turnover was more 
rapid than survivin-GFP (Figure 3H).  
Thus these data further indicate that 
survivin is less stable in the nucleus than 
in the cytoplasm.  
 
Survivin is preferentially degraded in 
the nucleus. 
Next we made nuclear and 
cytoplasmic extracts from asynchronous 
cultures of the stable cell lines of interest 
and loaded equivalent numbers of cells 
per lane (Figure 4).  Using tubulin and 
XRCC1 as markers of cytoplasmic and 
nuclear fractions respectively, we found 
that survivin-GFP, like endogenous 
survivin, was predominantly 
cytoplasmic (Figure 4A), but, consistent 
with our fluorescent imaging, expression 
of the NLS fused versions, 
survivinNLS(LANA)-GFP (Figure 4B), and 
survivinNLS(SV40)-GFP (Figure 4C), was 
extremely low. Moreover, there 
appeared to be little difference in 
expression between the two 
compartments which was surprising 
given that survivinNLS(LANA)-GFP and 
survivinNLS(SV40)-GFP were specifically 
sent to the nucleus.  However, upon 6h 
MG132 treatment, the levels of all 
versions of survivin, wild type and NLS-
fused, rose dramatically in the nucleus, 
further suggesting that survivin is less 
stable in the nuclear versus cytoplasmic 
compartment.  We noted that the levels 
of the NLS-fused forms of survivin also 
increased in the cytoplasmic fraction 
upon treatment with MG132 (Figures 4B 
and C), illustrating the nucleo-
cytoplasmic shuttling activity of the 
protein. 
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Survivin is degraded in the nucleus in 
G1. 
Survivin expression is normally limited 
to the G2/M stages of the cycle, with a 
rapid decline in its levels as cells exit 
mitosis and enter G1. A combination of 
factors contributes to the reduction in 
survivin during G1, including 
transcriptional repression, 
externalisation of the midbody at the end 
of mitosis, and proteolysis. This 
prompted us to further investigate 
survivin degradation during G1, using 
cells expressing the survivin-GFP, 
which is not subject to transcriptional 
repression. Cells were synchronised in 
G1 using mimosine (Figure 4D) then 
treated with 20 µM MG132 (Figure 4E) 
and fractionated (Figure 4F) to assess 
exogenous levels of survivin-GFP in the 
cytoplasm versus the nucleus. As with 
the asynchronous population following 
MG132 treatment (Figure 4A), survivin-
GFP was selectively up regulated in the 
nucleus after 6 h MG132 treatment in 
G1 arrested cells (Figure 4F). 
 
Degradation of nuclear survivin is 
mediated by Cdh1. 
Expression of survivin, and its partner 
protein, aurora-B kinase, is known to be 
regulated by proteolysis as cells exit 
mitosis (17,15). Degradation of aurora-B 
has been demonstrated to be mediated 
by the APC activated by cdc20 and cdh1 
(15), however, how survivin degradation 
is regulated has not been addressed.  
Thus to test whether survivin 
degradation was cdh1 or cdc20 
dependent, we transiently over 
expressed myc-cdh1 or myc-cdc20 (gifts 
from Dr. K. Ravid), in cells expressing 
the survivin constructs of interest.  
Immunoblotting analysis 24 h post-
transfection revealed that cells 
expressing either myc-cdh1 or myc-
cdc20 decreased the abundance of 
survivin-GFP, survivinNLS(LANA)-GFP 
and endogenous survivin in 
asynchronous cells (Figures 5A-C). This 
decrease in survivin levels was 
prevented by addition of MG132 for 1.5 
h post-transfection (Figure 5D).  (Note 
also, however, that the transfection 
efficiency with cdc20 was always lower 
than for cdh1).  
Quantitation of survivin expression from 
Figures 5A-D is shown in Figure 5E and 
plotted as a fraction of the expression in 
control cells.  
Cdh1 is a nuclear protein (12), 
while cdc20, whose level is low in G1, 
is more membranous/cytoplasmic (13). 
Thus, having established that survivin is 
degraded preferentially in the nucleus, 
we next asked whether depletion of cdh1 
could increase survivin levels. Cdh1 was 
depleted by siRNA from asynchronous 
HeLa cells, protein lysates were 
prepared 24 h post-transfection and 
analysed for survivin expression by 
immunoblotting. Despite an incomplete 
knock down of cdh1 (54%), survivin 
expression doubled under these 
conditions (Figure 5F).   
 
Nuclear survivin does not protect cells 
against apoptosis. 
To assess whether nuclear survivin is 
able to inhibit apoptosis, the cell lines 
indicated were subjected to a clonogenic 
survival assay after exposure to 
increasing doses of ionising X-
irradiation. Consistent with our previous 
data (4), expression of survivin-GFP 
conferred resistance to X-irradiation, 
compared with cells expressing GFP  
(Figure 6A) or GFPNLS-GFP (data not 
shown).  By contrast no resistance to 
radiation was conferred by the lines 
expressing survivinNLS(LANA)-GFP and 
survivinNLS(SV40)-GFP, indeed, these lines 
exhibited some increased sensitivity to 
this treatment, although less so than cells 
expressing survivinL98A-GFP.  
Next we induced apoptosis by 
treatment with recombinant TRAIL, and 
measured caspase activity in a 
fluorogenic tetrapeptide cleavage assay 
using the caspase-3 specific substrate, 
DEVD-AMC (Figure 6B). Lysates were 
prepared from cells expressing GFP, 
GFP-NLS-GFP, survivin-GFP, 
survivinNLS-GFP, or survivinL98A-GFP 
(as indicated) 0 or 60 minutes post-
treatment with TRAIL, and incubated 
for 1 h with DEVD-AMC.  In these 
assays survivin-GFP conferred 
protection against TRAIL mediated 
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apoptosis, but cells expressing 
survivinNLS-GFP exhibited similar and 
sometimes elevated levels of caspase-3 
activity to GFP and GFPNLS-GFP 
controls. The kinetics of the induction of 
caspase activity was most rapid in cells 
expressing the mutant version, 
survivinL98A-GFP, which we previously 
showed was nuclear and pro-apoptotic 
(4).  
As survivin is rapidly degraded 
in the nucleus, we asked whether 
inhibiting proteolysis could restore 
survivin’s ability to inhibit apoptosis.  
The cell lines indicated were exposed to 
5 Gy X-rays in the absence and presence 
of MG132. MG132 was removed after 6 
h and cell viability analysed 7 days later 
using an MTT assay (Figure 6C). In this 
assay inhibiting proteolysis rescued 
survivin’s anti-apoptotic activity 
possibly due to the increased 
cytoplasmic pool that accumulates under 
these conditions (see Figure 4C). To 
ascertain specifically whether the 
nuclear pool of survivin can be 
cytoprotective we repeated the TRAIL 
assay (Figure 6B) in the absence and 
presence of MG132, or MG132 and 
LMB.  In this assay, MG132 treatment 
caused a decrease in caspase activity in 
controls and experimental samples 
making it difficult to assess whether 
increased stability of the exogenously 
expressed protein specifically 
contributes to the reduced caspase 
activity.  However, the additional 
treatment of LMB caused an increase in 
apoptosis in survivin-GFP cells, while 
the level of caspase 3 activity in 
survivinNLS-GFP cells appeared to be 
unaffected by either treatment.  These 
data indicate that when stabilised and 
completely nuclear, survivin cannot 
inhibit apoptosis.  Taken together our 
present data suggest that forced 
expression of survivin in the nucleus is 
sufficient to prevent it from inhibiting 
apoptosis in cultured human cells.  
 
Discussion.  
Survivin is a nucleo-cytoplasmic 
shutting protein that is predominantly 
cytoplasmic when over expressed in 
cultured cells (2,9).  We, and others, 
have recently shown that this sub 
cellular localisation is dependent upon 
CRM1 (beta-exportin) and a rev-like 
NES in survivin’s linker region, between 
its BIR domain and C-terminal alpha-
helix (2-4,6-8). 
Here we demonstrate that 
survivin is preferentially degraded in the 
nucleus in a cdh1/APC-dependent 
manner. These findings are consistent 
with cdh1 mediated degradation of 
survivin in vitro (14), and the nuclear 
localisation of cdh1 in G1(12). 
Somewhat paradoxically, survivin 
appears to be devoid of destruction 
motifs recognised by the APC/C. 
However, survivin’s mitotic partner 
protein aurora-B has three putative D-
boxes, a KEN box and an A-box, and 
mutation of the cdh1 specific KEN and 
A-boxes stablise aurora-B suggesting 
that its destruction is mediated 
preferentially by cdh1 (15,16). In 
addition, aurora-B also exhibits 
accelerated clearance upon over 
expression of cdh1, increased stability 
upon cdh1 depletion and co-
immunoprecipitates with cdh1 in mitotic 
extracts (15,16). Thus, as survivin and 
aurora-B are both destroyed at the end of 
mitosis (14-17), it is formally possible 
that survivin relies on aurora-B’s 
consensus sequences for destruction. We 
are currently testing this hypothesis.  
In a previous report we found 
that a mutant form of survivin that 
accumulates in the nucleus could no 
longer protect cells against ionising 
radiation or TRAIL-induced apoptosis 
(4).  Corroborating data were recently 
presented by Stauber and co-workers (6-
8). However, these experiments raised 
the question as to whether sub cellular 
relocalisation alone was responsible for 
abrogating survivin’s anti-apoptotic 
activity, or whether the effect was 
mutant specific. Here, we have 
artificially forced wild type human 
survivin expression in the nucleus and 
observed that this relocation prevented 
survivin from acting as an inhibitor of 
apoptosis. Furthermore, in some cases 
we actually noted an increase in 
sensitivity to apoptotic stimuli, the 
reason for which is unclear. One 
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possibility may be that the sub cellular 
localisation of the exogenous protein 
influences the localisation of the 
endogenous protein. In a recent study 
Temme and co-workers also found that 
cells were more sensitive to apoptosis 
when they forced survivin expression in 
the nucleus, and interestingly they 
linked this observation to enhanced 
transcription of p53, and the pro-
apoptotic genes, Bad and Bax (5).   
Our present data appear to 
contradict the recent work by Stauber 
and co-workers (6), who reported that 
nuclear sequestration of murine survivin 
via deletion of the NES increased the 
stability of the protein, thus suggesting 
that it is preferentially degraded in the 
cytoplasm. However, it is possible that 
deletion of these residues could have 
affected the folding or stability of 
survivin specifically, rather than 
increased its stability as a result of its 
sub cellular relocalisation. (Note also 
that our experiments used stable cell 
lines rather than transiently transfected 
cells, which could have contributed to 
the different results). Differential 
stability due to sub cellular 
compartmentalisation has been noted for 
a number of proteins including p53 
whose localisation and stability is 
altered upon DNA damage (18). 
Furthermore, the survivin isoform Delta-
Ex3, which is nuclear when over 
expressed, (19,20), is also cleared from 
the cell more rapidly than wild type 
survivin (21), and may explain why 
endogenous survivin DeX3 is difficult to 
detect at the protein level (20,22). 
Interestingly, it has recently been 
reported that survivin degradation can 
also be facilitated by the XIAP 
association factor, XAF-1, in a 
proteasome dependent manner, which 
suggests that multiple pathways for 
ensuring the removal of survivin from 
interphase cells exist (24). 
Finally, survivin has a 
functional NES, but no NLS. Thus, one 
outstanding question is how is survivin 
gaining access to the nucleus?  Although 
the endogenous protein is small enough 
to enter the nucleus by diffusion even if 
dimerised, this is unlikely given the 
behaviour of the GFP tagged form. Of 
survivin’s known binding partners 
aurora-B has sequences that correspond 
to NLSs but appear non-functional in a 
nuclear targeting assay, and  INCENP 
has three functional NLSs (3).  
However, when over expressed in MCF 
cells, neither aurora-B nor INCENP was 
able to influence survivin localisation, 
which remained predominantly 
cytoplasmic (3). Another candidate for 
nuclear targeting is TD60, an RCC1-like 
protein, which has a putative NLS, and 
co localises with the chromosomal 
passenger proteins (23).  However, it 
should be noted that chromosomal 
passenger proteins have a cell cycle 
dependent expression, and whether they 
are present in interphase cells when 
survivin is over expressed is unknown. 
In conclusion, we have 
demonstrated that relocating survivin to 
the nucleus accelerates its degradation 
and prevents it from protecting cells 
against IR and inhibiting apoptosis. We 
have also shown that the presence of an 
NLS on survivin does not affect its 
mitotic function. Thus sequestering 
survivin in the nucleus could be very 
helpful in cancer therapy as it would 
resensitise cells to radiation without 
affecting proliferation of non-cancerous 
cells.  
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Figure Legends. 
Figure 1: Endogenous survivin is preferentially degraded in the nucleus. (A) Nuclear (N) 
and cytoplasmic (C) fractionation was carried out on HeLa cells that had been incubated in 
the absence (-) or presence (+) of MG132 (50 μM, 6 h). An increase in endogenous survivin 
was apparent upon proteasome inhibition in the nuclear (compare lanes 2 and 4), but not the 
cytoplasmic fraction (lanes 1 and 3).  (B) HeLa cells were incubated in the absence (-) or 
presence (+) 6 ng/ml LMB for 12 h to inhibit exportation of survivin from the nucleus.  This 
treatment alone caused a 30% reduction in survivin expression.   
 
Figure 2: Expression of survivin-GFP and survivinNLS-GFP constructs in HeLa cells. (A-
C) Interphase cells stably expressing the constructs indicated were probed with anti-lamin B 
antibodies (red) to show the nuclear margins, and DAPI to visualise the DNA (blue).  Right 
panels show a representative field of cells from each population (D-F). Mitotic cells as above 
were probed with anti-tubulin antibodies (red) and DAPI (blue). NLS-fusion caused nuclear 
sequestration of survivin-GFP in interphase but did not alter localisation during mitosis. 
 
Figure 3: SurvivinNLS-GFP is degraded more rapidly than survivin-GFP. (A) RT-PCR was 
performed on cells expressing survivin-GFP (lane 1), survivinNLS(LANA)-GFP (lane 2), and 
survivinNLS(SV40)-GFP (lane 3) and confirmed that mRNA was expressed in each line. (B) 
Lysates were prepared from cell lines expressing survivin-GFP or survivinNLS-GFP after the 
indicated times post treatment with 50 μM MG132, and immunoblots probed using anti-GFP 
antibodies.  To detect survivinNLS-GFP at adequate levels for quantitation a 6 h treatment with 
MG132 was required. (C) Quantification of ECL signals in (B): Survivin-GFP expression is 
represented by circles, and survivinNLS-GFP by triangles. (D and E) Treatment overnight with 
20 μM MG132 (lanes 2) followed by subsequent release into cycloheximide (50 μg/ml) to 
inhibit protein translation, (lanes 3-6) revealed that survivinNLS(LANA)-GFP degraded more 
rapidly than survivin-GFP. This experiment was performed twice with similar results. (F) 
Quantitation of immunoblots shown in D and E. (G and H) To assess the synthesis rate of 
survivin-GFP (time 0), or survivinNLS-GFP (time 0), cells were pulse labelled with 35S-
methionine for 2 h and immunoprecipitation carried out with anti-survivin antibodies 
(Novus).  Pixel intensities of bands (time 0) were similar: 255246 and 246678, assigned 100% 
in (H).  Cells were then subjected to a cold chase before immunprecipitation as above at 4, 8 
or 16 h.  Consistent with the immunoblotting experiments, survivinNLS-GFP turned over more 
rapidly than survivin-GFP. In (H) expression at time 0 is taken as 100%. Data graphed is the 
mean and standard deviation from two independent experiments. 
 
Figure 4: Survivin is preferentially degraded in the nucleus. Nuclear (N) and cytoplasmic 
(C) extracts were prepared from asynchronous HeLa cells expressing (A) survivin-GFP , (B) 
survivinNLS(LANA)-GFP, or (C) survivinNLS(SV40)-GFP.  Immunoblots were probed with anti-
tubulin and anti-XRCC1 antibodies to indicate cytoplasmic and nuclear fractions respectively. 
MG132 stabilised survivin-GFP in the nucleus, but did not alter its expression in the 
cytoplasmic fraction suggesting that it is preferentially degraded in the nucleus.  MG132 
caused increased expression of survivinNLS-GFP lines in both compartments, which may 
reflect the nuclear-cytoplasmic shuttling activity of these proteins. (D) To arrest cells in G1, 
cells were treated for 16 h with mimosine and DNA content analysed by FACS. (E) No 
change in G1 distribution was observed upon addition of MG132.  (F) Nuclear-cytoplasmic 
fractionation was carried out as in (A) on a G1 enriched population of survivin-GFP cells. As 
in (A), survivin-GFP was preferentially stabilised in the nuclear fraction upon MG132 
treatment.  
 
Figure 5: Cdh1 mediates survivin degradation in the nucleus. Asynchronous HeLa cells 
expressing (A) survivin GFP, (B) survivinNLS(LANA)-GFP (C) or not expressing any construct 
were transfected with pcDNA3 constructs containing cDNA to cdh1-myc or cdc20-myc and 
whole cell lysates prepared 24 h later.  To determine the level of survivin-GFP expression and 
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cdh1-myc or cdc20-myc expression, immunoblots were probed with anti-survivin and anti-
myc antibodies respectively. Note that, due to the similarity in size between the tubulin and 
cdh1-myc/cdc20-myc, two separate gels were run: tubulin indicates the loading for survivin 
blots. Overexpression of both cdh-myc and cdc20-myc decreased the expression of all forms 
of survivin, exogenous and endogenous. (D) The decrease in survivin expression observed 
upon over expression of cdh1 or cdc20 was reversed when cells were treated with MG132 (50 
μM for 1.5 h). (E) Quantification of blots in A-D, showing the level of survivin as a fraction 
of the control. Data is representative of a minimum of two independent experiments. (F) 
Cdh1 was depleted from HeLa cells using predesigned siRNA oligos. Immunblot analysis 
revealed a 54% decrease in cdh1 expression. This decrease was accompanied by a 200% 
increase in survivin levels 24 h post-transfection, when compared with the control (C) 
population treated with a scrambled oligo. Tubulin indicates equality in loading.  
 
Figure 6: SurvivinNLS-GFP is not cytoprotective. (A) HeLa cells stably expressing the 
constructs indicated were seeded at low density, exposed to X-irradiation, and colonies of 50 
or more cells counted 7 days post-irradiation.  Surviving fraction was plotted in logarithmic 
scale. Overexpression of survivin-GFP, but not survivinNLS-GFP, protected cells against 
irradiation.  Note that neither survivinNLS-GFP line was as sensitive to irradiation as 
survivinL98A-GFP. Data is representative of three independent experiments. Each experiment 
was performed in triplicate and error bars show standard deviation from the mean. Paired T-
test analysis revealed that at 2.5 Gy irradiation there was a significant difference between 
survivin-GFP expressing populations and those expressing survivinNLS(LANA)-GFP (P=0.031), 
survivinNLS(SV40)-GFP (P=0.047), or survivinL98A-GFP (P=0.037). The differences were not 
significant at higher doses of irradiation.(B) Caspase-3 activity assay. Apoptosis was induced 
by the addition of recombinant TRAIL. Cell lysates were analysed for their ability to cleave 
the caspase-3 specific substrate (DEVD-AMC), and relative fluorescence release measured 
spectroscopically. Overexpression of survivin-GFP inhibited caspase-3 activity, but activity 
remained high in survivinNLS-GFP lines. A paired T-test comparing TRAIL-treated survivin-
GFP cells with those expressing the NLS-fused survivin-GFP constructs or survivinL98A-GFP, 
revealed a significant difference in each case.  P-values in italics (above control and survivin-
GFP samples) were obtained by comparison with HeLa cells. We noted also that cells 
expressing GFP-NLS(LANA)-GFP also showed a significant difference in caspase-3 activity 
compared with HeLa cells alone, thus we compared GFP-NLS(LANA)-GFP and survivinNLS(LANA)-
GFP samples.  In this case the difference was also significant (P=0.046). (C) MTT Assay 
indicating mean survival with error bars indicating standard deviation.  Cell lines indicated 
were exposed to 5 Gy irradiation in the absence or presence of 50 μM MG132.  MG132 was 
maintained in the medium for 6h post-irradiation.  Cell viability, assessed 7 days post-
irradiation using an MTT assay, revealed that the expression of survivin-GFP prevented cell 
death induced by 5 Gy irradiation, and was unaffected by MG132 treatment (compare grey 
and white bars). A paired T-test (5 Gy v. 5 Gy + MG132 samples) revealed no significant 
difference in GFP and survivin-GFP expressing populations, but, a significant difference 
(P=0.03) in the survivinNLS-GFP cells. By contrast, the decreased viability observed with 
survivinNLS-GFP with exposure to 5 Gy (survivinNLS-GFP, grey bars) was restored upon 
stabilisation of the protein with MG132 (survivinNLS-GFP, white bars). (D) A caspase-3 
activity assay, as described for (B), was performed on cells that had been pretreated with no 
MG132 50 μM MG132 (6 h), or 50 μM MG132 and 10 ng/ml LMB (6 h) Time indicated is 
the duration of exposure to TRAIL; the mean and standard deviation from one experiment 
performed in triplicate is shown and is representative of two independent experiments. 
MG132 treatment alone reduced the extent of apoptosis in each sample, but interestingly, co-
treatment with LMB increased the caspase activity in survivin-GFP expressing cells, and had 
no significant effect (P>0.05) on cells expressing survivinNLS-GFP. These data indicate that 
nuclear survivin cannot inhibit apoptosis. 
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